Valuation: Imugene Limited

Market Cap 40.34M 27.82M 24.44M 22.46M 21.06M 39.46M 2.62B 271M 105M 1.3B 104M 102M 4.5B P/E 2026 *
-0.83x
P/E 2027 * -1.23x
Enterprise Value 40.04M 27.61M 24.25M 22.29M 20.9M 39.17M 2.6B 269M 104M 1.29B 104M 101M 4.47B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day-3.00%
1 week-15.65%
Current month-15.65%
1 month-22.40%
3 months-30.71%
6 months-70.15%
Current year-73.42%
1 week 0.1
Extreme 0.095
0.12
1 month 0.09
Extreme 0.09
0.12
Current year 0.09
Extreme 0.09
0.41
1 year 0.09
Extreme 0.09
0.48
3 years 0.09
Extreme 0.09
5.1
5 years 0.09
Extreme 0.09
21.25
10 years 0.09
Extreme 0.09
21.25
Manager TitleAgeSince
Chief Executive Officer - 2016-10-31
Director of Finance/CFO - 2025-03-03
Chief Tech/Sci/R&D Officer - 2023-08-31
Director TitleAgeSince
Chairman 70 2012-10-30
Director/Board Member - 2018-03-27
Director/Board Member 66 2019-04-22
Date Insider Type Main position Quantity % Market Cap.
12-18Fiscal year

Director

14,706 0.0047%
12-18Free

Director

14,706 0.0047%
12-18Free

Director

14,706 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
-3.00%-15.65%-74.06%-96.64% 27.85M
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +0.44%+6.66%+59.49%+95.84% 23.01B
Weighted average by Cap. +0.75%+8.71%+86.66%+140.71%

Financials

2026 *2027 *
Net sales - -
Net income -56.97M -39.3M -34.52M -31.72M -29.75M -55.74M -3.71B -383M -148M -1.83B -148M -144M -6.36B -42.79M -29.51M -25.92M -23.82M -22.34M -41.86M -2.78B -287M -111M -1.37B -111M -108M -4.77B
Net Debt -300K -207K -182K -167K -157K -293K -19.51M -2.01M -780K -9.64M -777K -760K -33.47M -1M -690K -606K -557K -522K -978K -65.04M -6.71M -2.6M -32.13M -2.59M -2.53M -112M
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
15
Date Price Change Volume
26-06-26 A$0.0970 -3.00% 3,033,839
26-06-25 A$0.1000 -4.76% 689,970
26-06-24 A$0.1050 -4.55% 1,977,853
26-06-23 A$0.1100 0.00% 968,623
26-06-22 A$0.1100 -4.35% 1,523,443
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0970AUD
Average target price
0.3067AUD
Spread / Average Target
+216.15%

Quarterly revenue - Rate of surprise